<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TYPHIM VI- <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">salmonella</span> typhi ty2 vi polysaccharide antigen injection, solution </strong><br>Sanofi Pasteur Inc.<br></p></div>
<h1><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine<br> Typhim Vi<span class="Sup">®</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">AHFS Category: 80:12</p>
<p><span class="Bold">Typh</span></p>
<p><span class="Bold Italics">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Typhim Vi<span class="Sup">®</span>, <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine, produced by Sanofi Pasteur SA, for intramuscular use, is a sterile solution containing the cell surface Vi polysaccharide extracted from<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> enterica </span>serovar<span class="Italics"> Typhi</span>,<span class="Italics"> S typhi </span>Ty2 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>. The organism is grown in a semi-synthetic medium. Casein derived raw materials are used early in manufacturing during the fermentation process. The capsular polysaccharide is precipitated from the concentrated culture supernatant by the addition of hexadecyltrimethylammonium bromide, and the product is purified by differential centrifugation and precipitation. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg) used for the inactivation of the bacterial culture. The potency of the purified polysaccharide is assessed by molecular size and O-acetyl content. Phenol, 0.25%, is added as a preservative. The vaccine contains residual polydimethylsiloxane or fatty-acid ester-based antifoam. The vaccine is a clear, colorless solution. Each dose of 0.5 mL is formulated to contain 25 mcg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7 ± 0.3), 4.150 mg of Sodium Chloride, 0.065 mg of Disodium Phosphate, 0.023 mg of Monosodium Phosphate, and 0.5 mL of Sterile Water for Injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="CP"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid fever</span> is an infectious disease caused by<span class="Italics"> S typhi</span>. Humans are the only natural host and reservoir for <span class="Italics">S typhi</span>; <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> result from the consumption of food or water that has been contaminated by the excretions of an acute case or a carrier.<span class="Italics"> S typhi </span>organisms efficiently invade the human intestinal mucosae ultimately leading to <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>; following a typical 10- to 14-day incubation period, a systemic illness occurs. The clinical presentation of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> exhibits a broad range of severity and can be debilitating. Classical cases have <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>; the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> increases step-wise over a period of days and then may remain at 102°F to 106°F over 10 to 14 days before decreasing in a step-wise manner. <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesions</span> known as rose spots may be present. <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> is common in older children and adults, while <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may occur in younger children. Among the less common but most severe complications are <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The course is typically more severe without appropriate antimicrobial therapy. The case fatality rate was reported to be approximately 10% to 20% in the pre-antibiotic era. (1) (2) (3) During the period of 1983 to 1991 in the US, the case fatality rate reported to the Centers for Disease Control and Prevention (CDC) was 0.2% (9/4010). (4) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> of the gallbladder can lead to the chronic carrier state.</p>
<p><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid fever</span> is still endemic in many countries of the world where it is predominantly a disease of school-age children and may be a major public health problem. Most cases of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> in the US are thought to be acquired during foreign travel. During the periods of 1975 to 1984 and 1983 to 1984, respectively, 62% and 70% of the cases of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> reported to the CDC were acquired during foreign travel; this compares to 33% of cases during 1967-1972. (5)</p>
<p>In 1992, 414 cases of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> were reported to the CDC. Of these 414 cases, 1 (0.2%) case occurred in an infant under one year of age; 77 (18.6%) cases occurred in persons one to nine years of age; 81 (19.6%) cases occurred in persons 10 to 19 years of age; 251 (60.6%) cases occurred in individuals ≥20 years of age; the age was not available for 4 (1%) cases. One <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was reported in 1991. (4) Domestic surveillance could underestimate the risk of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> in travelers since the disease is unlikely to be reported for persons who received diagnosis and treatment overseas. (6) </p>
<p>Approximately 2% to 4% of acute <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> cases develop into a chronic carrier state. The chronic carrier state occurs more frequently with advanced age, and among females than males. (2) (7) These non-symptomatic carriers are the natural reservoir for<span class="Italics"> S typhi </span>and can serve to maintain the disease in its endemic state or to directly infect new individuals. Outbreaks of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> are often traced to food handlers who are asymptomatic carriers. (8)</p>
<p>Two formulations were utilized in studies of the <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine. These included the liquid formulation which is identical to Typhim Vi vaccine and a lyophilized formulation.</p>
<p>The protective efficacy of each of these formulations of the <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine was assessed independently in two trials conducted in areas where <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> is endemic. A single intramuscular dose of 25 mcg was used in these efficacy studies. A randomized double-blind controlled trial with Typhim Vi vaccine (liquid formulation) was conducted in five villages west of Katmandu, Nepal. There were 6,908 vaccinated subjects: 3,454 received Typhim Vi vaccine and 3,454 in the control group received a 23-valent pneumococcal polysaccharide vaccine. Of the 6,908 subjects, 6,439 subjects were in the target population of 5 to 44 years of age. In addition, 165 children ages 2 to 4 years and 304 adults over 44 years of age were included in the study. The overall protective efficacy of Typhim Vi vaccine was 74% (95% confidence interval (CI): 49% to 87%) for blood culture confirmed cases of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> during 20 months of post-vaccination follow-up. (9) (10) (11)</p>
<p>The protective efficacy of the <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine, lyophilized formulation, was evaluated in a randomized double-blind controlled trial conducted in South Africa. There were 11,384 vaccinated children 5 to 15 years of age; 5,692 children received the Vi capsular polysaccharide vaccine and 5,692 in the control group received Meningococcal Polysaccharide (Groups A+C) Vaccine. The protective efficacy for the Vi capsular polysaccharide (lyophilized formulation) group for blood culture confirmed cases of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> was 55% (95% CI: 30% to 70%) overall during 3 years of post-vaccination follow-up, and was 61%, 52% and 50%, respectively, for years 1, 2, and 3. Vaccination was associated with an increase in anti-Vi antibodies as measured by radioimmunoassay (RIA) and enzyme-linked immunosorbent assay. Antibody levels remained elevated at 6 and 12 months post-vaccination. (11) (12)</p>
<p>Because of the low incidence of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span>, efficacy studies were not feasible in a US population.</p>
<p>Controlled comparative efficacy studies of Typhim Vi vaccine and other types of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccines have not been performed.</p>
<p>An increase in serum anti-capsular antibodies is thought to be the basis of protection provided by Typhim Vi vaccine. However, a specific correlation of post-vaccination antibody levels with subsequent protection is not available, and the level of Vi antibody that will provide protection has not been determined. Also, limitations exist for comparing immunogenicity results from subjects in endemic areas, where some subjects have baseline serological evidence of prior<span class="Italics"> S typhi </span>exposure, to naive populations such as most American travelers.</p>
<p>In endemic regions (Nepal, South Africa, Indonesia) where trials were conducted, pre-vaccination geometric mean antibody levels suggest that <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> with<span class="Italics"> S typhi </span>had previously occurred in a large percentage of the vaccinees. In these populations, specific antibody levels increased four-fold or greater in 68% to 87.5% of older children and adult subjects following vaccination. For 43 persons 15 to 44 years of age in the Nepal pilot study, geometric mean specific antibody levels pre- and 3 weeks post-vaccination were, respectively, 0.38 and 3.68 mcg antibody/mL by RIA; 79% had a four-fold or greater rise in Vi antibody levels. (9) (12)</p>
<p>Immunogenicity and safety trials were conducted in an adult US population. A single dose of Typhim Vi vaccine induced a four-fold or greater increase in antibody levels in 88% and 96% of this adult population for 2 studies, respectively, following vaccination (see<a href="#table1"> Table 1</a>). (10) (13)</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1 (10) (13): Vi ANTIBODY LEVELS IN US ADULTS 18 TO 40 YEARS OF AGE GIVEN TYPHIM Vi VACCINE</span></caption>
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="10%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="left" colspan="2">GEOMETRIC MEAN ANTIBODY LEVELS (mcg antibody/mL by RIA)</th>
<th class="Rrule" align="center"></th>
</tr>
<tr>
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center" valign="middle">N</th>
<th align="center">Pre</th>
<th class="Rrule" align="center">Post<br>(4 weeks)</th>
<th class="Rrule" align="center">% ≥4 FOLD<br>INCREASE</th>
</tr>
<tr class="Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center"></th>
<th class="Rrule" align="center" colspan="2">(95% CI)</th>
<th class="Rrule" align="center">(95% CI)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="center">Trial 1<br>(1 lot)</td>
<td class="Rrule" align="center" valign="middle">54</td>
<td align="center">0.16<br>(0.13 to 0.21)</td>
<td class="Rrule" align="center">3.23<br>(2.59 to 4.03)</td>
<td class="Rrule" align="center">96% (52/54)<br>(87% to 100%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">Trial 2<br>(2 lots combined)</td>
<td class="Rrule" align="center" valign="middle">97</td>
<td align="center">0.17<br>(0.14 to 0.21)</td>
<td class="Rrule" align="center">2.86<br>(2.26 to 3.62)</td>
<td class="Rrule" align="center">88% (85/97)<br>(81% to 94%)</td>
</tr>
</tbody>
</table>
<p>No studies of safety and immunogenicity have been conducted in US children. A double-blind randomized controlled trial evaluating the safety and immunogenicity of Typhim Vi vaccine was performed in 175 Indonesian children. The percentage of 2- to 5-year-old children achieving a four-fold or greater increase in antibody levels at 4 weeks post-vaccination was 96.3% (52/54) (95% CI: 87.3% to 99.6%), and in the study subset of 2-year-old children was 94.4% (17/18) (95% CI: 72.7% to 99.9%). The geometric mean antibody levels (mcg antibody/mL by RIA) for the 2- to 5-year-old children and the subset of 2-year-olds were, respectively, 5.81 (4.36 to 7.77) and 5.76 (3.48 to 9.53). (10) (11)</p>
<p>In the US Reimmunization Study, adults previously immunized with Typhim Vi vaccine in other studies were reimmunized with a 25 mcg dose at 27 or 34 months after the primary dose. Data on antibody response to primary immunization, decline following primary immunization, and response to reimmunization are presented in Table 2. Antibody levels attained following reimmunization at 27 or 34 months after the primary dose were similar to levels attained following the primary immunization. (10) (13) This response is typical for a T-cell independent polysaccharide vaccine in that reimmunization does not elicit higher antibody levels than primary immunization. The safety of reimmunization was also evaluated in this study (see<a href="#AR"> ADVERSE REACTIONS </a>section).</p>
<a name="table2"></a><table width="100%">
<caption><span>Table 2 (10) (13): US STUDIES IN 18- TO 40-YEAR-OLD ADULTS: KINETICS AND   PERSISTENCE OF Vi ANTIBODY<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> RESPONSE TO PRIMARY IMMUNIZATION WITH TYPHIM Vi VACCINE, AND RESPONSE TO REIMMUNIZATION AT 27 OR 34 MONTHS</span></caption>
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="16%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center"></th>
<th class="Rrule" align="center" valign="middle">PRE-DOSE 1</th>
<th class="Rrule" align="center" valign="middle">1<br>MONTH</th>
<th class="Rrule" align="center" valign="middle">11 MONTHS</th>
<th class="Rrule" align="center" valign="middle">18 MONTHS</th>
<th class="Rrule" align="center" valign="middle">27 MONTHS</th>
<th class="Rrule" align="center" valign="middle">34 MONTHS</th>
<th class="Rrule" align="center" valign="middle">1 MONTH POST-REIMMUNIZATION<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a>
</th>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>mcg antibody/mL by RIA</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Includes available data from all reimmunized subjects (subjects initially randomized to Typhim Vi vaccine, and subjects initially randomized to placebo who received open label Typhim Vi vaccine two weeks later).</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Group 1: Reimmunized at 27 months following primary immunization.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Not Done.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Antibody levels pre-reimmunization.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>Group 2: Reimmunized at 34 months following primary immunization.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="center">GROUP 1<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center">N<br>Level<a href="#footnote-1" class="Sup">*</a><br>95% CI</td>
<td class="Rrule" align="center">43<br>0.19<br>(0.14-0.26)</td>
<td class="Rrule" align="center">43<br>3.01<br>(2.22-4.06)</td>
<td class="Rrule" align="center">39<br>1.97<br>(1.31-3.00)</td>
<td class="Rrule" align="center">ND<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule" align="center">43<br>1.07<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a><br>(0.71-1.62)</td>
<td class="Rrule" align="center">ND</td>
<td class="Rrule" align="center">43<br>3.04<br>(2.17-4.26)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center">GROUP 2<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center">N<br>Level<br>95% CI</td>
<td class="Rrule" align="center">12<br>0.14<br>(0.11-0.18)</td>
<td class="Rrule" align="center">12<br>3.78<br>(2.18-6.56)</td>
<td class="Rrule" align="center">ND</td>
<td class="Rrule" align="center">10<br>1.21<br>(0.63-2.35)</td>
<td class="Rrule" align="center">ND</td>
<td class="Rrule" align="center">12<br>0.76<a href="#footnote-5" class="Sup">¶</a><br>(0.37-1.55)</td>
<td class="Rrule" align="center">12<br>3.31<br>(1.61-6.77)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1"></a><p></p>
<h2>Concurrently Administered Vaccines</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.1.1"></a><p></p>
<h3>Concomitant Administration of Typhim Vi and Menactra vaccine</h3>
<p class="First">In a double-blind, randomized, controlled clinical trial, 945 participants aged 18 through 55 years received Typhim Vi and Menactra vaccines concomitantly (N=469), or Typhim Vi vaccine followed one month later by Menactra vaccine (N=476). Sera were obtained approximately 28 days after each respective vaccination. The antibody response to Typhim Vi vaccine and to Menactra vaccine components were similar between groups.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Typhim Vi vaccine is indicated for active immunization for the prevention of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> caused by<span class="Italics"> S typhi </span>and is approved for use in persons two years of age or older. </p>
<p>Immunization with Typhim Vi vaccine should occur at least two weeks prior to expected exposure to<span class="Italics"> S typhi</span>. </p>
<p>Typhim Vi vaccine is not indicated for routine immunization of individuals in the United States (US). (14)</p>
<p>Selective immunization against <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> carrier, and 3) workers in microbiology laboratories who frequently work with<span class="Italics"> S typhi</span>. (14)</p>
<p><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> vaccination is not required for international travel, but is recommended for travelers to such areas as Africa, Asia, and Central and South America where there is a recognized risk of exposure to<span class="Italics"> S typhi</span>. Current CDC advisories should be consulted with regard to specific locales. Vaccination is particularly recommended for travelers who will have prolonged exposure to potentially contaminated food and water. However, even travelers who have been vaccinated should use caution in selecting food and water. (15)</p>
<p>There is no evidence to support the use of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccine to control common source outbreaks, disease following natural disaster or in persons attending rural summer camps. (14)</p>
<p>An optimal reimmunization schedule has not been established. Reimmunization every two years under conditions of repeated or continued exposure to the<span class="Italics"> S typhi </span>organism is recommended at this time. </p>
<p>For recommended primary immunization and reimmunization see<a href="#DAA"> DOSAGE AND ADMINISTRATION </a>section.</p>
<p>Typhim Vi vaccine should not be used to treat a patient with <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> or a chronic <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> carrier.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">TYPHIM Vi VACCINE IS CONTRAINDICATED IN PATIENTS WITH A HISTORY OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span> TO ANY COMPONENT OF THIS VACCINE.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> have been reported rarely in the post-marketing experience (see<a href="#AR"> ADVERSE REACTIONS </a>section).</p>
<p>The safety and immunogenicity of Typhim Vi vaccine in children under two years of age has not been established. As with other polysaccharide vaccines, the antibody response may be inadequate. The decision whether to vaccinate children under 2 years of age depends upon the risk incurred by the child on the basis of the epidemiological context.</p>
<p>Typhim Vi vaccine provides protection against the risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> related to<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi</span>, but gives no protection against<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> paratyphi A </span>or<span class="Italics"> B</span>, non-<span class="Italics">S typhi </span>species of<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> enterica </span>serovar<span class="Italics"> Typhi</span>, or other bacteria that cause enteric disease.</p>
<p>If the vaccine is used in persons deficient in producing antibodies, whether due to genetic defect, <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> disease, or immunosuppressive therapy, the expected immune response may not be obtained. This includes patients with asymptomatic or symptomatic HIV-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, severe combined <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span>, <span class="product-label-link" type="condition" conceptid="440072" conceptname="Hypogammaglobulinemia">hypogammaglobulinemia</span>, or agammaglobulinemia; altered immune states due to diseases such as <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, or generalized malignancy; or an immune system compromised by treatment with corticosteroids, alkylating drugs, antimetabolites or radiation. (16)</p>
<p>As with any vaccine, vaccination with Typhim Vi vaccine may not protect 100% of individuals.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Care is to be taken by the health-care provider for the safe and effective use of Typhim Vi vaccine.</p>
<p>EPINEPHRINE INJECTION (1:1000) MUST BE IMMEDIATELY AVAILABLE FOLLOWING IMMUNIZATION SHOULD AN ANAPHYLACTIC OR OTHER <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span> OCCUR DUE TO ANY COMPONENT OF THE VACCINE.</p>
<p>Prior to an injection of any vaccine, all known precautions should be taken to prevent adverse reactions. This includes a review of the patient's history with respect to possible <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the vaccine or similar vaccines.</p>
<p>Acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> or febrile illness may be reason for delaying use of Typhim Vi vaccine except when, in the opinion of the physician, withholding the vaccine entails a greater risk.</p>
<p><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> (<span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span>) has been reported following vaccination with Typhim Vi. Procedures should be in place to prevent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falling</span> injury and manage syncopal reactions.</p>
<p>A separate, sterile syringe and needle or a sterile disposable unit must be used for each patient to prevent the transmission of infectious agents from person to person. Needles should not be recapped and should be properly disposed.</p>
<p>Do not administer intravenously.</p>
<p>Safety and immunogenicity data from controlled trials are not available for Typhim Vi vaccine following previous immunization with whole-cell <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> or live, oral <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccine (see<a href="#AR"> ADVERSE REACTIONS </a>section).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>INFORMATION FOR VACCINE RECIPIENTS OR PARENTS/GUARDIANS</h2>
<p class="First">Before administration, healthcare providers should inform patients, parents or guardians of the benefits and risks of immunization with Typhim Vi vaccine.</p>
<p>Prior to administration of Typhim Vi vaccine, healthcare providers should ask patients, parents and guardians about the recent health status of the patient to be immunized.</p>
<p>Typhim Vi vaccine is indicated in persons traveling to endemic or epidemic areas. Current CDC advisories should be consulted with regard to specific locales.</p>
<p>Travelers should take all necessary precautions to avoid contact with or ingestion of contaminated food and water.</p>
<p>One dose of vaccine should be given at least 2 weeks prior to expected exposure.</p>
<p>Reimmunization consisting of a single-dose for US travelers every two years under conditions of repeated or continued exposure to the<span class="Italics"> S typhi </span>organism is recommended at this time. (14)</p>
<p>As part of the child's or adult's immunization record, the date, lot number, and manufacturer of the vaccine administered should be recorded. (17)</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>DRUG INTERACTIONS</h2>
<p class="First">There are no known interactions of Typhim Vi vaccine with drugs or foods.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.1"></a><p></p>
<h3>Concomitant Vaccine Administration</h3>
<p class="First">Typhim Vi was concomitantly administered with Menactra vaccine in individuals 18 through 55 years of age (see<a href="#CP"> CLINICAL PHARMACOLOGY </a>and<a href="#AR"> ADVERSE REACTIONS</a>). </p>
<p>No studies have been conducted in the US to evaluate interactions or immunological interference between the concurrent use of Typhim Vi vaccine and drugs (including antibiotics and antimalarial drugs), immune globulins or other vaccines (including common travelers vaccines such as <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, <span class="product-label-link" type="condition" conceptid="136330" conceptname="Acute nonparalytic poliomyelitis">poliomyelitis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> A, and <span class="product-label-link" type="condition" conceptid="441210" conceptname="Yellow fever">yellow fever</span>). </p>
<p>Typhim Vi vaccine must not be mixed with any vaccine in the same syringe. Separate injection sites should be used in case of concomitant administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</h2>
<p class="First">Typhim Vi vaccine has not been evaluated for its carcinogenic potential, mutagenic potential or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>PREGNANCY CATEGORY C</h2>
<p class="First">Animal reproduction studies have not been conducted with Typhim Vi vaccine. It is not known whether Typhim Vi vaccine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Typhim Vi vaccine should be given to a pregnant woman only if clearly needed. (14)</p>
<p>When possible, delaying vaccination until the second or third trimester to minimize the possibility of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> is a reasonable precaution. (18)</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>NURSING MOTHERS</h2>
<p class="First">It is not known whether Typhim Vi vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Typhim Vi vaccine is administered to a nursing woman.</p>
<p>There is no data on the use of this product in nursing mothers. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">Safety and effectiveness of Typhim Vi vaccine have been established in children 2 years of age and older. (10) (11) (See<a href="#DAA"> DOSAGE AND ADMINISTRATION </a>section.) FOR CHILDREN BELOW THE AGE OF 2 YEARS, SAFETY AND EFFECTIVENESS HAVE NOT BEEN ESTABLISHED.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse event information is derived from clinical trials and worldwide post-marketing experience.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>DATA FROM CLINICAL TRIALS</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to vaccine use and for approximating rates.</p>
<p>Safety of Typhim Vi vaccine, the US licensed liquid formulation, has been assessed in clinical trials in more than 4,000 subjects both in countries of high and low endemicity. In addition, the safety of the lyophilized formulation has been assessed in more than 6,000 individuals. The adverse reactions were predominately minor and transient local reactions. Local reactions such as <span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">injection site pain</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, and <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> almost always resolved within 48 hours of vaccination. Elevated oral temperature, above 38°C (100.4°F), was observed in approximately 1% of vaccinees in all studies. No serious or life-threatening systemic events were reported in these clinical trials. (10) (11)</p>
<p>Adverse reactions from two trials evaluating Typhim Vi vaccine lots in the US (18- to 40-year-old adults) are summarized in Table 3. No severe or unusual side effects were observed. Most subjects reported <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> upon direct pressure). Local adverse experiences were generally limited to the first 48 hours. (10) (11)</p>
<a name="table3"></a><table width="75%">
<caption><span>Table 3 (10) (11): PERCENTAGE OF 18- TO 40-YEAR-OLD US ADULTS PRESENTING WITH LOCAL OR SYSTEMIC REACTIONS WITHIN 48 HOURS AFTER THE FIRST IMMUNIZATION WITH TYPHIM Vi VACCINE</span></caption>
<col align="left" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<col align="center" valign="middle" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">REACTION</th>
<th class="Rrule" align="center">Trial 1<br>Placebo<br>N = 54</th>
<th class="Rrule" align="center">Trial 1<br>Typhim Vi vaccine<br>N = 54<br>(1 Lot)</th>
<th class="Rrule" align="center">Trial 2<br>Typhim Vi vaccine<br>N = 98<br>(2 Lots combined)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Local</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span></td>
<td class="Rrule" align="center">7 (13.0%)</td>
<td class="Rrule" align="center">53 (98.0%)</td>
<td class="Rrule" align="center">95 (96.9%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">4 (7.4%)</td>
<td class="Rrule" align="center">22 (40.7%)</td>
<td class="Rrule" align="center">26 (26.5%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">8 (14.8%)</td>
<td class="Rrule" align="center">5 (5.1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2 (3.7%)</td>
<td class="Rrule" align="center">5 (5.1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Systemic</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Rrule" align="center">8 (14.8%)</td>
<td class="Rrule" align="center">13 (24.0%)</td>
<td class="Rrule" align="center">4 (4.1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">7 (13.0%)</td>
<td class="Rrule" align="center">11 (20.4%)</td>
<td class="Rrule" align="center">16 (16.3%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">4 (7.4%)</td>
<td class="Rrule" align="center">3 (3.1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">2 (3.7%)</td>
<td class="Rrule" align="center">1 (1.9%)</td>
<td class="Rrule" align="center">8 (8.2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">2 (3.7%)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3 (3.1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Feverish (subjective)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">6 (11.1%)</td>
<td class="Rrule" align="center">3 (3.1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> ≥100°F</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (1.9%)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (1.9%)</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<p>No studies were conducted in US children. Adverse reactions from a trial in Indonesia in children one to twelve years of age are summarized in Table 4. (10) (11) No severe or unusual side effects were observed.</p>
<a name="table4"></a><table width="75%">
<caption><span>Table 4 (10) (11): PERCENTAGE OF INDONESIAN CHILDREN ONE TO TWELVE YEARS OF AGE PRESENTING WITH LOCAL OR SYSTEMIC REACTIONS WITHIN 48 HOURS AFTER THE FIRST IMMUNIZATION WITH TYPHIM Vi VACCINE</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">REACTIONS</th>
<th class="Rrule" align="center" valign="middle">N = 175</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Subjective feeling of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Local</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Soreness</td>
<td class="Rrule" align="center">23 (13.0%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">25 (14.3%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">12 (6.9%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></td>
<td class="Rrule" align="center">5 (2.9%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Impaired Limb Use</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Systemic</span></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Feverishness<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a>
</td>
<td class="Rrule" align="center">5 (2.9%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">0</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4139968" conceptname="Underactive">Decreased Activity</span></td>
<td class="Rrule" align="center">3 (1.7%)</td>
</tr>
</tbody>
</table>
<p>In the US Reimmunization Study, subjects who had received Typhim Vi vaccine 27 or 34 months earlier, and subjects who had never previously received a <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccination, were randomized to placebo or Typhim Vi vaccine, in a double-blind study. Safety data from the US Reimmunization Study are presented in Table 5. (10) (11) (13) In this study 5/30 (17%) primary immunization subjects and 10/45 (22%) reimmunization subjects had a local reaction. No severe or unusual side effects were observed. Most subjects reported <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and/or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> upon direct pressure). Local adverse experiences were generally limited to the first 48 hours. (10) (11) (13)</p>
<a name="table5"></a><table width="75%">
<caption><span>Table 5 (10) (11) (13): US REIMMUNIZATION STUDY, SUBJECTS PRESENTING WITH LOCAL AND SYSTEMIC REACTIONS WITHIN 48 HOURS AFTER IMMUNIZATION WITH TYPHIM Vi VACCINE</span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center" valign="middle">REACTION</th>
<th class="Rrule" align="center" valign="middle">PLACEBO<br>(N = 32)</th>
<th class="Rrule" align="center" valign="middle">FIRST IMMUNIZATION<br>(N = 30)</th>
<th class="Rrule" align="center" valign="middle">REIMMUNIZATION<br>(N = 45<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>)</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>At 27 or 34 months following a previous dose given in different studies.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold">Local</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span></td>
<td class="Rrule" align="center">2 (6%)</td>
<td class="Rrule" align="center">28 (93%)</td>
<td class="Rrule" align="center">44 (98%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Rrule" align="center">1 (3%)</td>
<td class="Rrule" align="center">13 (43%)</td>
<td class="Rrule" align="center">25 (56%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">Induration</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">5 (17%)</td>
<td class="Rrule" align="center">8 (18%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (3%)</td>
<td class="Rrule" align="center">5 (11%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold">Systemic</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Rrule" align="center">1 (3%)</td>
<td class="Rrule" align="center">11 (37%)</td>
<td class="Rrule" align="center">11 (24%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">5 (16%)</td>
<td class="Rrule" align="center">8 (27%)</td>
<td class="Rrule" align="center">5 (11%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">2 (7%)</td>
<td class="Rrule" align="center">1 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (3%)</td>
<td class="Rrule" align="center">1 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  Feverish (subjective)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">3 (10%)</td>
<td class="Rrule" align="center">2 (4%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> ≥100°F</td>
<td class="Rrule" align="center">1 (3%)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">1 (2%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.1"></a><p></p>
<h3>Solicited Injection Site and Systemic Reactions When Given With Menactra Vaccine</h3>
<p class="First">The majority (70%-77%) of solicited <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> at the Typhim Vi and at the Menactra injection sites were reported as Grade 1 and resolved within 3 days post-vaccination. The most common systemic reactions were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (41% when Menactra and Typhim Vi were given concomitantly; 42% when Typhim Vi was given with Placebo, and 33% when Menactra vaccine was given alone one month after Typhim Vi vaccination) and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (38% when Menactra vaccine and Typhim Vi were given concomitantly; 35% when Typhim Vi was given with Placebo, and 27% when Menactra vaccine was given alone one month after Typhim Vi vaccination). <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> ≥40.0°C and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were not reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>DATA FROM WORLDWIDE POST-MARKETING EXPERIENCE</h2>
<p class="First">In addition to reports in clinical trials, worldwide voluntary adverse events reports received since market introduction of Typhim Vi vaccine are listed below. This list includes serious events and/or events which were included based on severity, frequency of reporting or a plausible causal connection to Typhim Vi vaccine. Because these events were reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to vaccination.</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span><br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span></li>
<li>General disorders and administration site condition<br><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection site pain</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, flu-like episode</li>
<li><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span><br><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, allergic-type reactions such as <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>; <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span></li>
<li>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span><br><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>, cervical <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span><br><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> with and without <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span></li>
<li><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory system disorders</span><br><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2.1"></a><p></p>
<h3>Additional Adverse Events</h3>
<p class="First">Post-marketing reports of <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, bilateral <span class="product-label-link" type="condition" conceptid="4161546" conceptname="Retinitis">retinitis</span>, and <span class="product-label-link" type="condition" conceptid="4025831" conceptname="Arthritis mutilans">polyarthritis</span> have been reported in patients who had also received other vaccines; however, a causal relationship has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>REPORTING OF ADVERSE EVENTS</h2>
<p class="First">Reporting by parents and patients of all adverse events occurring after vaccine administration should be encouraged. Adverse events following immunization with vaccine should be reported by the health-care provider to the US Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS). Reporting forms and information about reporting requirements or completion of the form can be obtained from VAERS through a toll-free number 1-800-822-7967 or visit the VAERS website at http//www.vaers.org. (17)</p>
<p><span class="Bold">Health-care providers also should report these events to the Pharmocovigilance Department, Sanofi Pasteur Inc., Discovery Drive, Swiftwater, PA 18370, or call 1-800-822-2463.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DAA"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The syringe or vial and its packaging should also be inspected prior to use for evidence of leakage, premature activation of the plunger, or a faulty tip seal. If any of these conditions exists, the vaccine should not be administered.</p>
<p>For intramuscular use only. Do NOT inject intravenously.</p>
<p>The immunizing dose for adults and children is a single injection of 0.5 mL. The dose for adults is typically given intramuscularly in the deltoid, and the dose for children is given IM either in the deltoid or the anterolateral thigh. The vaccine should not be injected into the gluteal area or areas where there may be a nerve trunk.</p>
<p>A reimmunizing dose is 0.5 mL. Reimmunization consisting of a single dose for US travelers every two years under conditions of repeated or continued exposure to the<span class="Italics"> S typhi </span>organism is recommended at this time. (14)</p>
<p>The syringe is intended for single use only, must not be reused, and must be disposed of properly and promptly following its use.</p>
<p>The skin at the site of injection first should be cleansed and disinfected. Tear off upper seal of vial cap. Cleanse top of rubber stopper of the vial with a suitable antiseptic and wipe away all excess antiseptic before withdrawing vaccine.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Syringe, without needle, 0.5 mL, NDC 49281-790-88. Packaged as NDC 49281-790-51.</p>
<p>Vial, 20 Dose, NDC 49281-790-38. Packaged as NDC 49281-790-20.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1</dt>
<dd>Levine MM, et al. New knowledge on pathogenesis of bacterial enteric <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as applied to vaccine development. Microbiol. Rev. 47: 510-550, 1983</dd>
<dt>2</dt>
<dd>Levine MM. <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid Fever</span> Vaccines. p 333-361. In Vaccines, Plotkin SA, Mortimer EA, eds. W.B. Saunders, 1988</dd>
<dt>3</dt>
<dd>Levine MM, et al. <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid Fever</span> Chapter 5, In: Vaccines and Immunotherapy. Stanley J. Cryz, Jr., Editor. pp 59-72, 1991</dd>
<dt>4</dt>
<dd>CDC. Summary of Notifiable Diseases, United States 1992. MMWR 41: No. 55, 1993</dd>
<dt>5</dt>
<dd>Ryan CA, et al. <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the United States, 1975-1984: Increasing Role of Foreign Travel. Rev Infect Dis 11:1-8, 1989</dd>
<dt>6</dt>
<dd>Woodruff BA, et al. A new look at <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> vaccination. Information for the practicing physician. JAMA 265: 756-759, 1991</dd>
<dt>7</dt>
<dd>Ames WR, et al. Age and sex as factors in the development of the <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid</span> carrier state, and a method for estimating carrier prevalence. Am J Public Health 33: 221-230, 1943</dd>
<dt>8</dt>
<dd>CDC. <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid fever</span> - Skagit County, Washington. MMWR 39: 749-751, 1990</dd>
<dt>9</dt>
<dd>Acharya IL, et al. Prevention of <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span> in Nepal with the Vi capsular polysaccharide of <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi. N Engl J Med 317: 1101-1104, 1987</dd>
<dt>10</dt>
<dd>Unpublished data available from Sanofi Pasteur Inc., compiled 1991</dd>
<dt>11</dt>
<dd>Unpublished data available from Sanofi Pasteur SA</dd>
<dt>12</dt>
<dd>Klugman KP, et al. Protective activity of Vi capsular polysaccharide vaccine against <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">typhoid fever</span>. The Lancet, 1165-1169, 1987</dd>
<dt>13</dt>
<dd>Keitel WA, et al. Clinical and serological responses following primary and booster immunization with <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhi Vi capsular polysaccharide vaccines. Vaccines 12: 195-199, 1994</dd>
<dt>14</dt>
<dd>Recommendations of the Immunization Practices Advisory Committee (ACIP). <span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Immunization. MMWR 43: No. RR-14, 1994</dd>
<dt>15</dt>
<dd>CDC. Health Information for International Travel 2001-2002. Atlanta: US Department of Health and Human Services, Public Health Service, 2001</dd>
<dt>16</dt>
<dd>ACIP: Use of vaccines and immune globulins in persons with altered immunocompetence. MMWR 42: No. RR-4, 1993</dd>
<dt>17</dt>
<dd>CDC. Vaccine Adverse Event Reporting System - United States. MMWR 39: 730-733, 1990</dd>
<dt>18</dt>
<dd>ACIP: Update on Adult Immunization. MMWR 40: No. RR-12, 1991</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Product Information as of March 2014.</p>
<p>Manufactured by:<br><span class="Bold">Sanofi Pasteur SA</span><br>Lyon, France<br>US Govt License #1724</p>
<p>Distributed by:<br><span class="Bold">Sanofi Pasteur Inc.</span><br>Swiftwater PA 18370 USA<br>1-800-VACCINE (1-800-822-2463)</p>
<p>968190-942501</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Label</h1>
<p class="First">NDC<span class="Bold"> 49281-790-88</span></p>
<p><span class="Bold">Typh<br>0.5 mL</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi<br>Polysaccharide<br>Vaccine<br>Typhim Vi<span class="Sup">®</span></span></p>
<p>IM only</p>
<p><span class="Bold Italics">Rx only</span></p>
<p><span class="Bold">Sanofi Pasteur</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1fbe7f-2995-45dd-92f3-7baccaab85d9&amp;name=typhim-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Carton</h1>
<p class="First">NDC<span class="Bold"> 49281-790-51</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi Polysaccharide Vaccine<br>Typhim Vi<span class="Sup">®</span></span></p>
<p>Single Dose Prefilled Syringe</p>
<p><span class="Bold">FOR INTRAMUSCULAR ADMINISTRATION.</span></p>
<p>For indications and directions see enclosed package circular.</p>
<p><span class="Bold">Typh</span></p>
<p><span class="Bold">0.5 mL</span></p>
<p><span class="Bold Italics">Rx only</span></p>
<p><span class="Bold">SANOFI </span>PASTEUR</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5 mL Syringe Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1fbe7f-2995-45dd-92f3-7baccaab85d9&amp;name=typhim-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 Dose Vial Label</h1>
<p class="First">NDC <span class="Bold">49281-790-38</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi<br>Polysaccharide<br>Vaccine – Typhim Vi</span><span class="Sup">®</span></p>
<p><span class="Bold">Typh</span></p>
<p><span class="Bold">20</span><br>DOSES</p>
<p>IM only<br>For indications and directions see<br>enclosed package insert.<br>Store at 2° to 8°C (35° to 46°F).<br><span class="Bold">DO NOT FREEZE.</span></p>
<p><span class="Bold Italics">Rx only</span></p>
<p>US Govt License #1724<br>Manufactured by:<br><span class="Bold">Sanofi Pasteur SA</span><br>Lyon France</p>
<p>Distributed by:<br><span class="Bold">Sanofi Pasteur Inc.</span><br>Swiftwater PA 18370 USA<br>1-800-VACCINE (1-800-822-2463)</p>
<p><span class="Bold">Sanofi Pasteur</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 Dose Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1fbe7f-2995-45dd-92f3-7baccaab85d9&amp;name=typhim-03.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 20 Dose Vial Carton</h1>
<p class="First">NDC <span class="Bold">49281-790-20</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="192819" conceptname="Typhoid fever">Typhoid</span> Vi<br>Polysaccharide Vaccine<br>Typhim Vi<span class="Sup">®</span></span></p>
<p><span class="Bold">Typh</span></p>
<p><span class="Bold">20</span><br>DOSES</p>
<p><span class="Bold Italics">Rx only</span></p>
<p><span class="Bold">SANOFI </span>PASTEUR</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 20 Dose Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ad1fbe7f-2995-45dd-92f3-7baccaab85d9&amp;name=typhim-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TYPHIM VI 		
					</strong><br><span class="contentTableReg"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">salmonella</span> typhi ty2 vi polysaccharide antigen injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-790</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">SALMONELLA</span> TYPHI TY2 VI POLYSACCHARIDE ANTIGEN</strong> (<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">SALMONELLA</span> TYPHI TY2 VI POLYSACCHARIDE ANTIGEN) </td>
<td class="formItem"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">SALMONELLA</span> TYPHI TY2 VI POLYSACCHARIDE ANTIGEN</td>
<td class="formItem">25 ug  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">4.15 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC, DIHYDRATE</strong></td>
<td class="formItem">0.065 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</strong></td>
<td class="formItem">0.023 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PHENOL</strong></td>
<td class="formItem">1.25 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">0.5 mL  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-790-51</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-790-88</td>
<td class="formItem">0.5 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49281-790-20</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:49281-790-38</td>
<td class="formItem">10 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103936</td>
<td class="formItem">11/28/1994</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi Pasteur Inc.
							(086723285)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Pasteur SA</td>
<td class="formItem"></td>
<td class="formItem">578763542</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>47d28f8b-8293-4e16-a084-cc7936faa9b7</div>
<div>Set id: ad1fbe7f-2995-45dd-92f3-7baccaab85d9</div>
<div>Version: 4</div>
<div>Effective Time: 20140404</div>
</div>
</div> <div class="DistributorName">Sanofi Pasteur Inc.</div></p>
</body></html>
